Have doubled over last year, 4th quarter triple coming as PanC-DX to be released to market along with drug testing/GE kits and Renevia for reconstructive surgery in EU. Talking billions in revenue. BTX best kept secret, but not for long.
Bump...let's keep things in perspective. PanC-DX bladder and lung positive results, cancer diagnostic products on track for 4th Q release.
BioTime, Inc. (NYSE MKT: BTX) today announced that Chief Executive Officer Michael D. West, PhD will present at the Jefferies 2015 Global Healthcare Conference to be held in New York on June 1-4, 2015. Dr. West will provide an overview of the company and an update on product development in his presentation at 3:00 PM EDT on Wednesday, June 3, 2015.
Duh!!......investors listen up, there is a stock, ticker BTX and they are the leader with the field of regenerative medicine.....and they just got upgraded to strong buy by some financial analyst. Buy you idiots!
Third deal in last couple months. GE, Beckmann Institute and now UC Davis all believing in Biotimes embryonic stem cell monopoly.
Title: BioTime's Clinical Grade Stem Cells From Subsidiary ES Cell International to Be Used in Planned CIRM-Funded Preclinical Studies of Huntington's Diseas
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 27, 2015-- BioTime, Inc. today announced that the clinical-grade human Embryonic Stem (hES) cell lines from BioTime's wholly-owned subsidiary ES Cell International Pte Ltd (ESI, Singapore) will be used by UC Irvine scientist Dr. Leslie Thompson to continue her promising research in the use of stem cells to treat Huntington's disease under a $5 million grant from the California Institute for Regenerative Medicine (CIRM). The CIRM grant will further support a collaboration between ESI and UC Davis's good-manufacturing-practice (GMP) laboratory for the creation of the GMP grade cells needed in Dr. Thompson's preclinical and potentially subsequent clinical studies.
This collaboration is an example of BioTime's strategy to leverage collaborations and potentially generate future revenues by placing its hES cells in a wide array of medical applications that BioTime could not otherwise address with its own resources. ESI provides its hES cells as both inexpensive research-grade cells through its ESI BIO division and as GMP-compliant clinical grade cells for translation into clinical applications, allowing researchers to conduct research with hES cells that can also be used in the clinic.
Good move, you are very lucky to have discovered BTX at such a bargin!
We ate up Geron, and growing into the premiere stem stock and still under radar. Should be another double by years end and be at $100 stock by end of 2016. buy, hold, be rich.
Haha....FEAR....SELL....ahhhhhh-hahaha! Nice job jepro/bb! Really good job of bashing. Fact is AST two dendritic vaccines getting good results so far, and same goes for their spine OPC1.
Not getting my shares bozo!